Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group

Fig. 4

Serious adverse events trajectories of groups pRLDA (remission-low) and pMDA (moderate) and subgroups plMDA and phMDA. RA, rheumatoid arthritis; pRLDA, patients with persistent remission or low disease activity; pMDA, patients with persistent moderate disease activity; plMDA, patients with persistent lower-moderate disease activity; phMDA, patients with persistent higher-moderate disease activity

Back to article page
\